Medicus Pharma Ltd.
MDCX
Positions held
Your positionsMDCX isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | $135,069 | Enterprise value | $12.94M | Trailing P/E | — | Forward P/E | -0.19 |
| PEG | — | Price / book | -3.11 | Beta | -0.30 | Dividend yield | 0.00% |
| Revenue growth | — | Earnings growth | — | Gross margin | 0.0% | Operating margin | 0.0% |
| Profit margin | 0.0% | ROE | -74.5% | ROA | -110.7% | Debt / equity | — |
| Current ratio | 1.57 | Free cash flow | -$16.16M | Analyst recommendation | none | Mean target | $4.50 |
| 52w high | $139.00 | 52w low | $0.08 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | |
|---|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — | — |
| Net income | -$11.6M | -$9.0M | -$8.2M | -$16.0M | -$6.2M | — |
| Gross margin | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — |
| Operating income | -$11.5M | -$8.6M | -$7.8M | -$15.4M | -$6.0M | — |
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $0.0M | $0.0M | $0.0M | $0.0M | — |
| Op margin | — | — | — | — | — |
| Net income | -$35.4M | -$11.2M | -$5.3M | -$1.7M | — |
| Gross margin | — | — | — | — | — |
| Gross profit | — | — | — | — | — |
| Operating income | -$34.4M | -$11.2M | -$2.7M | -$1.0M | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-08 · Medicus Pharma Outlines Clinical Development Strategy Across Three Drug Programs Following $90 Million in Financing
2026-10-08 · Medicus Pharma targets partnerships and clinical milestones as oncology pipeline advances
2026-10-08 · Medicus Pharma Highlights Three Years of Progress and Outlines Potential Path to Long Term Value
2026-09-29 · Medicus Pharma files streamlined Phase 2b/3 prostate cancer trial design with FDA
2026-09-21 · Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
2026-09-21 · Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
2026-09-16 · What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
2026-09-12 · Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
2026-09-10 · Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study
2026-09-10 · Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
Price (daily)
Full chart · RSI · MACD · patterns